Finn
PFE Pharmaceuticals · Large cap · Drugmaker · Healthcare · Thesis updated November 8, 2026

Pfizer raises guidance as core cancer and acquired drugs accelerate

01 Running thesis

A strong core fighting heavy patent losses

Pfizer's post-COVID transition is gaining traction. The core non-COVID portfolio is outperforming expectations, accelerating to 7 percent operational growth in the third quarter of 2026. This strength allowed management to raise full-year revenue guidance by $1.5 billion. Cancer and acquired drugs are bright spots, with the launched and acquired portfolio jumping 32 percent.

However, the rest of the business is struggling to find a bottom. COVID-19 revenue guidance was previously cut to $4 billion for the year. The acquired pipeline has also taken hits, including a recent $4.3 billion impairment charge after clinical setbacks for an acquired lung cancer asset and the withdrawal of Oxbryta.

The biggest long-term test remains the 2026 through 2030 patent cliff. Pfizer resolved a major tariff risk and expanded its cost savings target to $9.7 billion by 2029. Yet cost cuts cannot replace lost blockbusters. The company is leaning on its new obesity asset berobenatide and the cancer drug Elrexfio to fill the void.

Finn's view is cautious. Valuation is fair, but growth and performance scores remain weak. To win over investors, Pfizer needs its remaining Seagen assets and obesity pipeline to deliver before patent losses accelerate and price controls bite harder.

Nov 2026▲Q3 2026 earnings showed a faster turnaround. Non-COVID revenue growth hit 7 percent operationally, and launched or acquired products surged 32 percent, leading to a $1.5 billion guidance raise.
Aug 2026→Q2 2026 showed strong non-COVID growth and removed the Section 232 tariff risk. However, COVID guidance was cut to $4 billion and a $4.3 billion pipeline impairment highlighted execution risks.
May 2026▲Q1 2026 gave the bull case real support. The non-COVID business grew 7 percent operationally, launched and acquired products grew 22 percent, and Seagen assets grew 20 percent.
May 2026▼Pfizer's Q1 2026 filing added a new tariff risk. Section 232 tariffs on imported patented drugs and ingredients could phase in starting July 31, 2026, with the final impact still unknown.
Feb 2026▼The 2025 Form 10-K made the patent cliff risk more concrete. Pfizer said it expects a significant revenue reduction from exclusivity expirations in 2026 through 2030.
Nov 2025▼IRA pricing pressure became more visible in Pfizer's Q3 2025 filing. The company cited higher manufacturer discounts as a drag on net prices for products including Vyndaqel and Ibrance.
02 Business model

Patents turn science into cash

Pfizer makes money by discovering, developing, making, and selling medicines and vaccines. The best years for a drug are usually when patents protect it from cheap copycat drugs. After patents expire, generic or biosimilar rivals can push sales and prices down fast.

The company spends heavily on research and development. It also buys or licenses drugs from other companies when it wants to add growth faster than its own labs can provide it. Seagen is the current example, giving Pfizer a larger cancer drug base.

The model breaks when old blockbusters fade before new ones are ready. That is Pfizer's core test now. Management is aggressively executing cost realignment programs, targeting $9.7 billion in total net savings through 2029 to improve margins and support reinvestment.

03 Product portfolio

The drugs that matter most

Cash cow

Vyndaqel family and Vyndamax

These heart drugs are key revenue drivers. A legal settlement extended Vyndamax patent exclusivity to 2031, which gives Pfizer more cash flow visibility.

Cash cow

Eliquis

Eliquis is a major blood thinner sold with a partner. It faces Medicare price negotiation pressure under the IRA, with a new Medicare price required from January 1, 2026.

Growth engine

Padcev and Seagen oncology assets

Cancer is becoming Pfizer's main growth engine. Padcev saw huge gains after expanding its approved indication to include muscle invasive bladder cancer.

Growth engine

Nurtec

Acquired from Biohaven, this migraine treatment is a material growth driver and helped push the launched and acquired portfolio up 32 percent.

Steady

Prevnar family

Prevnar vaccines are part of Pfizer's broad vaccine base. They help diversify the business beyond cancer and specialty drugs.

Cash cow

Comirnaty and Paxlovid

The COVID-19 vaccine and antiviral still matter, but demand is falling from pandemic highs. The company expects just $4 billion from this franchise in 2026.

Option

Berobenatide

This obesity drug is a long-term option. Pfizer is aggressively advancing the asset into Phase 3 trials, targeting first approvals in 2028.

04 Business segments

One segment, two big markets

United States revenue59%flat
International revenue41%flat

Pfizer reports Biopharma as its sole reportable segment, newly updated with a Global Hospital and Biosimilars organization. The geographic mix shown uses 2025 revenue: U.S. revenue was $37.1 billion and International revenue was $25.5 billion.

05 Risk factors

What could still break

Patent cliff hits faster than launches grow

High impact · High odds

Pfizer expects a significant revenue reduction from patent and regulatory exclusivity losses in 2026 through 2030. Vyndamax protection to 2031 helps, but it does not protect the whole company. If new products fail to scale, revenue can shrink even if the science looks promising.

We watchWatch management's updates on 2026 through 2030 exclusivity losses and growth from launched and acquired products.

Drug pricing pressure lowers net prices

High impact · High odds

The IRA is already hitting net prices through Medicare changes and manufacturer discounts. Eliquis is among the first drugs subject to Medicare price negotiation. The OBBBA could add more pressure by reducing federal healthcare spending and increasing price controls.

We watchWatch net price comments for Eliquis, Vyndaqel, Ibrance, and other Medicare-exposed products.

Pipeline execution falters

High impact · Medium odds

Drug development is risky, and Pfizer needs wins to replace older drugs. A recent $4.3 billion impairment charge for an acquired lung cancer asset and Oxbryta shows that acquired assets are not immune to clinical setbacks. A few more weak readouts could make the patent cliff harder to offset.

We watchWatch clinical trial data readouts, especially for MEVPRO-1 in Q1 2027 and the berobenatide obesity program.

COVID-19 revenues fall below expectations

Medium impact · Medium odds

The COVID-19 franchise is finding a lower floor than previously expected. Guidance was cut to $4 billion in 2026. Further structural declines would force the core business to work harder to offset the drag.

We watchWatch infection rates and quarterly revenue guidance for Comirnaty and Paxlovid.
06 Quick answers

In one breath

Why is Pfizer stock still under pressure?

Despite strong non-COVID growth, investors are worried about the 2026 through 2030 patent cliff. Pricing rules, pipeline setbacks, and fading COVID-19 demand also weigh on the stock.

What is the biggest bull case for Pfizer?

The bull case is that Pfizer's post-COVID rebuild is working. Non-COVID revenue grew 7 percent operationally in the third quarter of 2026, leading to a guidance raise. Cost cuts also expanded to $9.7 billion.

What is Seagen doing for Pfizer?

Seagen gives Pfizer a stronger cancer drug portfolio. Its assets are growing fast, and Padcev recently won a major label expansion, making the deal a clear growth driver.

What should investors watch next?

Watch Q1 2027 pipeline readouts for MEVPRO-1, the start of berobenatide Phase 3 obesity studies, and Seagen growth. These will show whether Pfizer can offset its patent losses.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Pfizer Q3 2026 earnings transcript
  2. Pfizer Q2 2026 earnings transcript
  3. Pfizer Q1 2026 Form 10-Q
  4. Pfizer 2025 Form 10-K
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Pfizer Inc. in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today